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The combination of dehydroepiandrosterone, transdermal 
testosterone, and growth hormone as an adjuvant therapy 
in assisted reproductive technology cycles in patients aged 
below 40 years with diminished ovarian reserve 
Kırk yaş altı azalmış over rezervli hastaların yardımla üreme 
teknikleri sikluslarında adjuvan tedavide dehidroepiandesteron, 
transdermal testosteron ve büyüme hormonu kombinasyonu
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Özet
Amaç: Azalmış over rezervli (AOR) hastaların ART sikluslarında transdermal testosteronj DHEA ve büyüme hormonu (BH) kombinasyonunun etkinliğini 
değerlendirmek.
Gereç ve Yöntemler: Seksen bir siklusu olan 33 AOR hastalarının siklusları yaş ve over rezervi eşleştirilmiş 52 hastanın 102 konvansiyone IVF/ICSI 
protokolü retrospektif kohort içermektedir. Bu çalışma 12 haftalık DHEA tedavisine son 4 hafta transdermal testosterone eklenmesiyle, luteal başlangıçlı 
BH verilmesinin daha önce başarısız veya iptal IVF/ICSI siklusları olan AOR hastalardaki sonuçlarını değerlendirmiştir.
Bulgular: On dört mm üzerindeki folikül sayısı, oosit sayısı, metafaz 2 oosit sayısı ve fertilizasyon oranı ISIK protokolünde (IP) ciddi olarak daha yüksektir. 
Embryo transferi başına klinik gebelik IP grubunda %38,2’dir (13/34). Siklus iptali IP grubunda %54,5’den (24/44) %8,1’e (3/37) düşmüştür ve devam 
eden gebelik oranı IP grubunda %35,3’dür.
Sonuç: Bizim çalışmamız, transdermal testosteron, DHEA ve BH’nin ovaryan follikülogenezi uyararak çok kötü yanıt verenlerde bile klinik gebelik elde 
edilebileceğini göstermiştir. J Turk Soc Obstet Gynecol 2015;2:60-5
Anahtar Kelimeler: Azalmış over rezerv, DHEA, transdermal testosteron, büyüme hormonu, IVF/ICSI
Abstract
Objective: To evaluate to the efficacy of testosterone, dehydroepiandrosterone (DHEA) and growth hormone (GH) supplementations in patients with 
diminished ovarian reserve (DOR) in assisted reproductive technology (ART) cycles.
Materials and Methods: A retrospective cohort including 33 women with 81 ART cycles were aged and ovarian reserve matched 52 women with 
102 conventional in vitro fertilization (IVF)/intra-cytoplasmic sperm injection (ICSI) protocol. Administration of DHEA for 12 weeks and transdermal 
testosterone for 4 weeks as pretreatment adjuvant and luteal start GH in DOR patient treatment arm compared to conventional IVF/ICSI cycles.
Results: The number of follicles >14 mm, number of oocytes, number of metaphase 2 oocytes and fertilisation rate were significantly higher in ISIK 
protocol (IP). The clinical pregnancy rate (CPR) per embryo transfer of the IP was 38.2% (13/34). The cancellation rate of cycles decreased significantly 
from 54.5 % (24/44) to 8.1% (3/37) with the IP, while the OPR was 35.3% (12/34).
Conclusions: Our study has shown that even the poorest responders could achieve clinical pregnancy after inducing ovarian folliculogenesis with a 
combination of transdermal testosterone, DHEA and GH. J Turk Soc Obstet Gynecol 2015;2:60-5
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Introduction
Diminished ovarian reserve (DOR) is one of the most 
challenging conditions for an assisted reproductive technology 
(ART) specialist due to the high cancellation rate and low 
live birth rate (LBR). Although many controlled ovarian 
hyperstimulation (COH) protocols have been proposed for 
patients with DOR, similar LBRs have been observed(1). 
ART cycle outcomes in DOR patients have been claimed to 
be improved by pre- and co-treatment with several drugs as 
adjuvants to COH, such as administration of transdermal 
testosterone, dehydroepiandrosterone (DHEA), and growth 
hormone (GH)(2-4). 
Androgens have an important role in ovarian folliculogenesis, 
and a decrease in clinical pregnancy rate in patients undergoing 
IVF has been shown to be related to lower testosterone levels(5). 
Gleicher et al. demonstrated significant hypoandrogenism 
in women with DOR compared with age-matched women 
with normal ovarian reserve(6). Although there is no strong 
consensus on the positive effect of DHEA supplementation for 
patients with DOR(7), recent literature favors the administration 
of DHEA(8-10). 
The efficacy of testosterone, DHEA, and GH supplementation 
has been studied in patients with DOR separately; however, 
the combination of these alternative regimens has not yet 
been reported. This study evaluated the outcome of in vitro 
fertilization (IVF)/intra-cytoplasmic sperm injection (ICSI) 
cycles. Before the commencement of COH, we combined a 12-
week DHEA administration with the addition of transdermal 
testosterone for the last 4 weeks and GH supplementation 
initiated in the late luteal phase in patients with DOR who had 
previously cancelled or failed IVF/ICSI cycles. 
Materials and Methods
This study was conducted in Başkent University Faculty of 
Medicine, Department of Obstetrics and Gynecology, Division 
of Reproductive Endocrinology and IVF Unit (Adana, Turkey), 
and approved by the Ethics Committee of Başkent University. 
We retrospectively enrolled 81 IVF/ICSI cycles in 33 patients 
from October 2010 to December 2013. We compared 44 cycles 
in 33 women who had resulted in cancellation or pregnancy 
failure with 37 cycles during which a novel treatment protocol 
was used, which we called the ISIK protocol (IP). Before the 
start of COH, 12 weeks of DHEA 25 mg t.i.d in combination 
with 25 mg transdermal testosterone gel daily for the last 4 
weeks, and 3 IU GH administration was started in the late luteal 
phase. 
We also defined a control group through the retrospective 
analysis of 2155 IVF/ICSI cycles that were performed during 
the same time period. In total, 51 patients were found to be 
appropriate for comparing with the study group in terms of 
age and ovarian reserve parameters. The patients in the control 
group had undergone 102 conventional IVF/ICSI cycles in our 
clinic during this time period.
The diagnosis of DOR was made in accordance with the 
European Society of Human Reproduction and Embryology 
(ESHRE) Consensus of Bologna criteria for the study cohort 
and control group(11). The previous 44 cycles of the 33 patients 
consisted of 24 flexible gonadotropin releasing hormone (GnRH) 
antagonist cycles with 300 IU of recombinant follicle-stimulating 
hormone (FSH), 20 cycles of clomiphene citrate, and low-dose 
(150 IU) recombinant FSH combined with a GnRH antagonist. 
These patients were scheduled for IP, which was initiated by the 
administration of 75 mg/d DHEA (Biosterone 25 mg, Interpharm, 
Switzerland) for 8 weeks. Throughout DHEA administration, 
antral follicle count was examined upon each menstruation. 
Thereafter, 25 mg/d transdermal testosterone gel (Testogel 50 
mg, Bayer Pharma AG, Berlin, Germany), 75 mg/d DHEA, and 
an oral contraceptive pill (Yasmin, Bayer Pharma AG, Berlin, 
Germany) for 21 days starting on the first day of menstruation. 
Growth hormone was started as 1 mg/3 IU (Genotropin, Pfizer 
Inc., New York, NY, USA) on day 21 of the last menstrual cycle. 
Subcutaneous injection of GH was applied every other day 
(q.o.d.) till the start of menstruation. DHEA and testosterone gel 
application were stopped on the first day of the menstrual cycle. 
On the third day of the menstrual cycle, GH administration 
was shifted to daily 3 IU injections and in addition to this, 
0.1 mg/ml of the GnRH agonist triptoreline (Decapeptyl; 
Ferring Pharmaceuticals, Switzerland) for 3 days and 5 mg/d 
letrozol (Femara; Novartis Pharma AG, Basel, Switzerland) for 
5 days were commenced. Administration of gonadotropins 
was also started on the same day with 150 IU of recombinant 
FSH (Puregon; MSD, The Netherlands), plus 150 IU of pure 
human menopausal gonadotropin (HMG) (Menopur; Ferring 
Pharmaceuticals, Switzerland). A GnRH antagonist (Orgalutran; 
MSD, The Netherlands) was added to this regimen when the 
leading follicle reached 14 mm (Figure 1).
After the leading follicle reached >17 mm, 10.000 IU of 
hCG (Pregnyl ampul; MSD, The Netherlands) and 0.2 mg/
ml triptorelin were injected. Transvaginal ultrasound-guided 
oocyte retrieval was performed 36 h after this dual trigger with 
a 17-gauge needle under sedation with 1% propofol (Fresenius 
Kabi, Germany). The oocyte-corona complexes (OOC) were 
Figure 1. ISIK protocol schematic view
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denuded, and ICSI was performed after 2-h incubation. 
Embryos were transferred on day 3. 
All patients had luteal support with intravaginal daily 90-mg 
progesterone (Crinone 8% gel, Merck Serono) and 0.1 mg/ml 
triptorelin on the third day after embryo transfer(12). Clinical 
pregnancy was defined as the presence of at least one gestational 
sac with detectable fetal cardiac activity under transvaginal 
ultrasonography. 
Statistical Analysis
Data are expressed as means ± SD. The baseline differences 
among the previous and study cycles were analyzed by one-way 
analysis of variance. A Bonferroni test was used for post hoc 
comparisons. In contingency tables, the χ2 test or the two-sided 
Fisher’s exact test was performed. P<0.05 was considered to 
indicate statistical significance. Data were analyzed using SPSS 
for Windows (version 16.0; SPSS, Inc., Chicago, IL).
Results
Baseline characteristics of the two protocols are shown in Table 
1. Although baseline characteristics were similar, the anti-
Müllerian hormone (AMH) level of the control group was higher. 
The duration of COH cycles was significantly longer in the ISIK 
protocol. However, the number of follicles >14 mm, number of 
oocytes, number of metaphase 2 oocytes and fertilization rate 
were significantly higher in IP (Table 1). Although the fertilization 
rate of the control group was lower than IP, the difference was not 
statistically significant. The fertilization rate of the study group 
was statistically lower than IP (Table 1). The mean number of 
grade 1 and transferred embryos were similar in both groups 
(Table 1). In the IP group, four patients had 2 IVF/ICSI cycles 
(33 patients had 37 cycles and 34 transfers). Three cycles were 
repeated due to fertilization failure. The fourth patient had a 
second IP cycle due to the negative result of the first cycle. 
The clinical pregnancy rate per embryo transfer of IP was 38.2% 
(13/34) (Table 2). The cancellation rate of cycles significantly 
decreased from 54.5% (24/44) to 8.1% (3/37) with IP, and the 
ongoing pregnancy rate was 35.3% (12/34 embryo transfer). 
However, clinical pregnancy rate (CPR) and LBR in the control group 
were significantly lower than IP (22% and 10%, respectively). 
Although the implantation rate (IR) was lower in the control 
group than IP, the difference did not reach statistical significance. 
Discussion
This protocol was developed in two clinics based on long 
discussions and the accumulation of data supporting the use 
of DHEA and transdermal testosterone in patients with DOR. 
Unexpected and astonishing oocyte yields and deliveries in 
patients with very high FSH levels, ranging from 25-89 IU/L 
during a relatively short period of time (unpublished data) led 
us to attempt this protocol in a well-defined group of poor-
responder patients. We analyzed the data retrospectively in 
such a patient cohort from whom all records were available for 
the previous cancelled or failed cycles. 
Our study has shown that even the poorest responders could 
achieve clinical pregnancy after inducing ovarian folliculogenesis 
with a combination of transdermal testosterone, DHEA, and 
GH. 
Although short-term DHEA supplementation in DOR does not 
increase AMH levels, an increase in antral follicle count after 
16 weeks of supplementation has been reported recently(13). 
Moreover, DHEA supplementation has been associated with 
unexpected spontaneous pregnancies prior to IVF(10). This 
effect of DHEA may be explained by the finding of reduction 
in the embryonic aneuploidy rate(14). In an animal model, 10 
weeks of DHEA supplementation in 6 female sheep resulted 
in increased expression of the proliferation marker Ki-67 in 
granulosa cells and follicular AMH expression in the pre-antral 
and early antral follicle stages(15). Surprisingly, a recent but 
previous meta-analysis of human studies by the same authors 
demonstrated that DHEA supplementation in DOR had no 
significant effect on oocyte yield and CPR(16). There was a 
reduction in the androgenic milieu during the late follicular 
stage in patients with DOR, and de los Santos et al. suggested 
that long-term androgen supplementation for oocyte priming 
could increase recruitment of small antral follicles rather than 
increase intra-ovarian androgen levels in women with DOR(17). 
The role of androgens in folliculogenesis remains a matter of debate. 
Although short-term administration of high doses of androgens 
in monkeys did not increase the number of large antral follicles, 
the total number of growing pre-antral and small antral follicles 
was increased 2.5-4.5- fold(18). The first randomized controlled 
trial (RCT) on testosterone pre-treatment in women with DOR 
demonstrated that even though IVF/ICSI cycle outcomes were 
similar, testosterone pre-treatment improved ovarian sensitivity 
and follicular response to gonadotropins(19). Another RCT of 
transdermal testosterone pre-treatment (TTP) demonstrated 
significantly improved cycle outcomes(20). These two RCTs did 
not comment on the dermatologic adverse effects of androgen 
supplementation and there have been no reports of DHEA and 
transdermal testosterone combination therapy. Our retrospective 
cohort is the first clinical study of this combined approach. The 
cycle outcomes in our study group support the results of other 
clinical trials in which DHEA and TTP were used as adjuvants. 
Moreover, a meta-analysis by Bosdou et al. demonstrated better 
cycle outcomes when androgens or androgen-modulating agents 
were used in patients with patients DOR(21).
The current study demonstrated that total gonadotropin use 
was relatively low with the conventional protocol. This was 
related to shorter COH duration and the administration of 20 
cycles of clomiphene citrate. The shorter COH duration could 
be related to higher basal FSH levels in the poorest responders, 
which might lead to earlier dominant follicle development that 
impaired follicular synchronization in the COH cycle. Rapid 
follicular development could also lead to premature luteinization 
and the addition of GnRH antagonist, which is proposed to 
prevent this, may also suppress the growth of the aftercoming 
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follicular cohort. Pre-treatment with DHEA and testosterone 
together with GH might increase intra-ovarian androgen levels, 
resulting in slower follicle growth with IP, which could enhance 
the development of a few more antral follicles and allow for a 
more homogenous maturation. For the time being, we do not 
know which agent or agents mediate this response.
In addition to the meta-analysis by Duffy et al., another meta-
analysis of GH co-treatment in COH cycles in DOR also 
demonstrated that the addition of GH improved the rate of 
clinical pregnancy and LBR(4,22). It has been shown that oral 
DHEA supplementation increased serum insulin-like growth 
factor-I concentrations, which positively affected follicular 
development and oocyte quality(23); GH supplementation 
in DOR may function in a similar manner. Our study also 
demonstrated that the combination of DHEA and GH might 
have additive effects that cause higher oocyte numbers and 
better cycle outcomes in DOR patients. On the other hand, our 
COH cycle management was different from other published 
protocols. We administered a GnRH analogue for 3 days 
together with recombinant FSH plus HMG, a total of 300 IU/d, 
and added 5 mg/d letrazole for 5 days. The aim of the GnRH 
agonist ultra-short application was to induce endogenous FSH 
together with exogenous gonadotropins. Letrozole was added 
to induce a similar effect and to reduce the peripheral estrogen, 
Table 2. IVF/ICSI outcomes of study groups
Conventional protocol control 
group (Number=102)
Conventional protocol 
(Number=44)
ISIK protocol 
(Number=37)
p
CPR (%) 22.0 (11/50)a 0 (0/20)b 38.2 (13/34)c 0.001
LBR (%) 10.0 (5/50)a 0 (0/20)b 35.3 (12/34)c 0.002
IR (%) 12.0±35.79 0 (0/20)a 26.47±37.4b 0.001
Cancellation Rate (%) 51 (52/102)a 54.5 (24/44)a 8.1 (3/37)b 0.001
CPR: Clinical pregnancy rate, LBR: Live birth rate, IR: Implantation rate, the pregnancy and cancellation rates were per embryo transfer, a and b, a and c, b and c= The difference was statistically 
significant between these groups
Table 1. Basal characteristics of study groups 
Conventional protocol 
control group (n=102)
Conventional protocol 
(n=44)
ISIK protocol (n=37) p
Age 33.94±3.38 33.34±4.29 - 0.16
FSH 14.49±14.78 11.7±12.9 - 0.48
AFC 2.68±1.40 2.73±1.68 - 0.84
AMH 0.26±0.15a 0.17±0.09b - 0.038
Duration of infertility 5.67±4.33 4.54±2.91 - 0.12
E2 level on day of hCG 598.15±683.09 491.68±464.34 520.6±566.78 0.81
P4 level on day of hCG 0.84±1.55 0.77±1.14 0.43±0.25 0.1
Endometrium thickness 9.4±1.86 9.43±2.02 9.38±2.14 0.92
Duration of COH 8.96±2.21a 8.0±3.23a 10.44±3.3b 0.02
Total gonadotrophin use 2253.12±1174.36 1869.07±1043.66 2307.03±1238.58 0.11
The number of follicule >14 mm 3.57±2.14a 3.52±2.49a 5.38±2.96b 0.003
The number of oocytes 3.48±2.06a 2.2±2.26b 4.31±2.79c 0.001
The number of M II oocytes 2.09±1.59a 1.92±2.06a 3.34±1.9b 0.003
The number of GV 0.75±1.15 0.41±0.64 0.93±1.28 0.47
Fertilisation rate 55.35±35.32 41.31±37.07a 67.16±30.96b 0.04
The number of transferred embryos 1.26±0.59 1.44±0.51 1.5±0.5 0.71
The number of grade 1 embryos 0.32±0.58 0.5±0.61 0.34±0.48 0.31
The number of grade 2 embryos 1.0±0.53 0.88±0.75 1.14±0.64 0.2
AFC: Antral follicle count, AMH: Anti-Müllerian Hormone, GV: Germinal vesicle, COH: controlled ovarian hyperstimulation  a and b, a and c, b and c = The difference was statistically 
significant between these groups
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which might be a preventive measure against a premature 
LH surge. Also, a relatively low estrogenic milieu resembling 
physiologic levels may lead to better endometrial growth for 
improved implantation and cycle outcomes. We stopped 
administration of DHEA and testosterone throughout the COH 
cycle due to potential adverse effects of excess androgens on 
the endometrium. Weissman et al. reported increased follicular 
phase progesterone levels in COH cycles during which DHEA 
was co-administered(24). DHEA was very recently shown to 
induce a progesterone rise that resolves rapidly after cessation 
of the drug, which may be detrimental to the endometrium(25).
Oocyte donation is not permitted in Turkey; thus, IP was developed 
as a last resort in our cohort so as to perform IVF/ICSI with patients’ 
own gametes. The unexpected higher pregnancy rates could be 
attributed to the enrolment of relatively younger women with DOR. 
Another interesting finding was the higher fertilization rate in the IP 
group, which could be explained by improved oocyte quality due 
to the addition of GH and DHEA supplementation, which reduced 
embryo aneuploidy in a previous study(14). Although the embryo 
qualities of both groups were similar, the increased fertilization rate 
appeared to be a function of both DHEA and GH. 
A major limitation of this study is that it was a retrospective 
cohort using the same group of women with DOR. In addition, 
the combination of effective treatment modalities may mask the 
independent effects of individual medications. It should be noted 
that patients with DOR use a variety of nutritional and herbal 
supplements, and continue their use even with conventional 
controlled ovarian stimulation protocols. In addition, attempting 
an RCT is difficult in patients DOR because most patients want 
to be in the study group and will not give informed consent. 
We tried to establish a novel pre- and co-treatment modality 
using drugs that are individually effective on a physiologic 
basis, which when combined may have had synergistic effects 
on oocytes, embryos, and possibly on endometrial quality. The 
combination of the androgens DHEA, and TTP with GH should 
be evaluated in large-scale, well-designed, randomized trials 
that involve both young and advanced-age patients with DOR. 
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